ANTIMICROBIAL RESISTANCE PANEL
CUUR DiagnosticsTM is dedicated to maintaining the largest data set of infectious disease targets available in the world.
It’s clear that after hundreds of years of steady medical breakthroughs, the public health crisis of Antimicrobial Resistance poses a very real possibility of medical setbacks. Developing new medicines isn’t enough. The discovery of new antimicrobials is too slow to keep pace with how quickly microbes are evolving rather we need to preserve the effectiveness of the antimicrobials we have. Just as important, it’s critical we move away from the broad over-prescription of antibiotics towards more targeted therapy.
The CUUR Diagnostics proprietary Antimicrobial Resistance Panel and Technology Solutions empower healthcare providers to make targeted treatment decisions sooner — reducing inappropriate antimicrobial use and the spread of resistance. Our advanced molecular technologies detect clinical problematic and prevalent antibiotic resistance genes that lead to resistance to some of the most commonly prescribed antibiotics including penicillin, cephalosporins, monobactams, carbapenems, macrolides and fluoroquinolones. CUUR Diagnostics can help guide patient treatment, detect emerging threats, and prevent the spread of antibiotic resistance and while informing local providers to prevent spread and protect people on a global level.
|β-lactamase||β-lactamase (class D)|
|β-lactamase||AmpC β-lactamase (Class C)|
|β-lactamase||Extended Spectrum β-lactamase (Class A)|
|β-lactamase||verona integron-encoded metallo-β-lactamase|
|Carbapenemase||Carbapenemase (Class A)|
|Carbapenemase||Carbapenemase (Class B)|
|Carbapenemase||Carbapenemase (Class D)|
|Van||vanC2/3 is specific to E. casseliflavus|
|Van||vanC1 is present in E. gallinarum and specific to this species. The assay serves as ABR and species ID assay|
|Sul||sulfonamide-resistant dihydropteroate synthase Sul1|
|Sul||sulfonamide-resistant dihydropteroate synthase Sul2|
D I A G N O S T I C S
- CDC reports every year in the United States alone over 2,000,000 Antimicrobial Resistant infections and at least 23,000 deaths
- $20 Billion Direct Healthcare Annual Spend in US